4.7 Article

RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics

Journal

NATURE IMMUNOLOGY
Volume 17, Issue 12, Pages 1352-1360

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/ni.3575

Keywords

-

Categories

Funding

  1. European Research Council under the European Union's Seventh Framework Programme (FP7) / ERC grant [310857]
  2. Vienna Science and Technology Fund (WWTF) [LS14-031]
  3. Celgene Austria
  4. National Institutes of Health [R01AI067946]
  5. Boehringer Ingelheim Fonds
  6. Austrian Science Fund (FWF) [M1809-B19]
  7. French Agence Nationale de la Recherche [ANR-13-BSV1-0031]
  8. Austrian Science Fund (FWF) [M 1809] Funding Source: researchfish
  9. European Research Council (ERC) [310857] Funding Source: European Research Council (ERC)
  10. Austrian Science Fund (FWF) [M1809] Funding Source: Austrian Science Fund (FWF)

Ask authors/readers for more resources

RASGRP1 is an important guanine nucleotide exchange factor and activator of the RAS-MAPK pathway following T cell antigen receptor (TCR) signaling. The consequences of RASGRP1 mutations in humans are unknown. In a patient with recurrent bacterial and viral infections, born to healthy consanguineous parents, we used homozygosity mapping and exome sequencing to identify a biallelic stop-gain variant in RASGRP1. This variant segregated perfectly with the disease and has not been reported in genetic databases. RASGRP1 deficiency was associated in T cells and B cells with decreased phosphorylation of the extracellular-signal-regulated serine kinase ERK, which was restored following expression of wild-type RASGRP1. RASGRP1 deficiency also resulted in defective proliferation, activation and motility of T cells and B cells. RASGRP1-deficient natural killer (NK) cells exhibited impaired cytotoxicity with defective granule convergence and actin accumulation. Interaction proteomics identified the dynein light chain DYNLL1 as interacting with RASGRP1, which links RASGRP1 to cytoskeletal dynamics. RASGRP1-deficient cells showed decreased activation of the GTPase RhoA. Treatment with lenalidomide increased RhoA activity and reversed the migration and activation defects of RASGRP1-deficient lymphocytes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available